Thu, December 1, 2011
Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011

Amylin Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. -annual-piper-jaffray-healthcare-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Amylin Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Healthcare Conference -- SAN DIEGO, Nov. 23, 2011 /PRNewswire/ --

Amylin Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Healthcare Conference

[ ]

SAN DIEGO, Nov. 23, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: [ AMLN ]) will be presenting at the 23rd Annual Piper Jaffray Health Care Conference in New York on Wednesday, November 30, 2011 at 1:00 p.m. ET/10:00 a.m. PT. Mark Foletta, Senior Vice President and Chief Financial Officer, Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate website at [ www.amylin.com ], and a recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at [ www.amylin.com ].

SOURCE Amylin Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.amylin.com ]


Publication Contributing Sources